NCT05271409: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- State
- Under way
- Phase
- Phase 3
- People
- 139 taking part
- Started
- 30 Aug 2022
- Primary completion
- 20 Nov 2025
- Arms
- Satralizumab
- Results
- None posted
- 9 Mar 2022: Trial registered
- 30 Aug 2022: Trial started